论文部分内容阅读
目的探讨乳酸菌联合Ⅰ型干扰素对溃疡性结肠炎的治疗疗效。方法将120例溃疡性结肠炎患者随机分为对照组60例和观察组60例。对照组口服复方乳酸菌胶囊治疗,每次1~2粒,3次/d;观察组在对照组的基础上皮下注射Ⅰ型干扰素,每次1×106~3×106 ml,3次/周,疗程3个月。比较2组患者的近期疗效,治疗前后的临床症状评分,满意度及不良反应发生率。结果治疗后,观察组的总有效率90.00%显著高于对照组75.00%(P<0.05);2组患者的临床症状评分显著改善,且观察组的改善情况明显优于对照组(P<0.05);观察组满意度为96.77%明显高于对照组77.42%(P<0.05);2组不良反应发生率无差异(P<0.05)。结论乳酸菌联合Ⅰ型干扰素对溃疡性结肠炎患者疗效显著,且不良反应率小,满意度高,应在临床推广使用。
Objective To investigate the therapeutic effect of lactic acid bacteria combined with type Ⅰ interferon on ulcerative colitis. Methods 120 patients with ulcerative colitis were randomly divided into control group (60 cases) and observation group (60 cases). The control group was treated with oral compound lactic acid bacteria capsule once or twice a day for 3 times per day. The observation group was subcutaneously injected with type I interferon (1 × 106 ~ 3 × 106 ml, 3 times / week on the basis of the control group) , Treatment for 3 months. The curative effect, clinical symptom scores, satisfaction and incidence of adverse reactions before and after treatment were compared between two groups. Results After treatment, the total effective rate in the observation group was 90.00%, which was significantly higher than that in the control group (75.00%, P <0.05). The scores of clinical symptoms in the two groups were significantly improved, and the improvement in the observation group was significantly better than that in the control group ). The degree of satisfaction in the observation group was 96.77%, which was significantly higher than that in the control group (77.42%, P <0.05). There was no difference in the incidence of adverse reactions between the two groups (P <0.05). Conclusion lactic acid bacteria combined with type Ⅰ interferon has a significant effect on patients with ulcerative colitis, and the adverse reaction rate is small, high satisfaction, should be used in clinical promotion.